Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy

被引:144
|
作者
Hua, Yi-Jun [2 ,3 ]
Han, Fei [1 ,2 ]
Lu, Li-Xia [1 ,2 ]
Mai, Hai-Qiang [2 ,3 ]
Guo, Xiang [2 ,3 ]
Hong, Ming-Huang [2 ,3 ]
Lu, Tai-Xiang [1 ,2 ]
Zhao, Chong [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China
[2] State Key Lab Oncol So China, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510060, Guangdong, Peoples R China
关键词
Nasopharyngeal carcinoma; Intensity modulated radiotherapy; Re-irradiation; Survival; Prognosis; PROGNOSTIC-FACTORS; RADIATION-THERAPY; EXPERIENCE; REIRRADIATION; OSTEORADIONECROSIS; RETREATMENT; SURGERY;
D O I
10.1016/j.ejca.2012.06.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the long-term treatment outcome in patients with recurrent nasopharyngeal carcinoma NPC) treated with salvage intensity modulated radiotherapy (IMRT). Materials and methods: One hundred and fifty one previously irradiation NPC patients with recurrent disease and re-irradiated by IMRT between 2001 and 2006 had been reviewed. The disease was re-stage I in 7, re-stage II in 21, re-stage III in 50 and re-stage IV in 73. Thirty-seven patients received concurrent chemotherapy, 39 had induction chemotherapy and 75 had radiotherapy alone. Results: All patients completed the planned IMRT. The median volume of the recurrent gross target volume of nasopharynx (rGTVnx) was 42.2 cm(3) (range 1.5-146.3 cm(3)). The median mean re-irradiation dose to the rGTVnx was 70.4 Gy (range 62.1-77.6 Gy). The median follow-up time after re-irradiation was 40.0 months (range 1.9-116.9 month). The 5-year local control rate (LCR) and overall survival rate (OS) for re-stage I, II, III, IV were 80.0%, 85.0%, 80.0%, 78.7% and 71.4%, 62.9%, 35.5%, 30.2%, respectively. Multivariate analysis indicated that rT classification (hazard ratio (HR), 2.02; 95% confidence interval (CI), 1.03-3.97; P = 0.04) and the volume of rGTVnx (HR, 2.05; 95% CI, 1.31-3.22; P < 0.01) were independent predictors for OS. Patients (39.0%) with re-stage III or IV disease experienced Grade 3 or 4 late toxicities. Conclusion: Re-irradiation by IMRT for recurrent NPC resulted in encouraging local control. The clinical outcome for patients with early re-stage diseases was satisfactory. Further investigations, focus on optimising radiation dose and establishing effective treatment strategies, are warranted for advanced recurrent disease in order to improve overall survival and minimise late toxicity. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3422 / 3428
页数:7
相关论文
共 50 条
  • [1] Long-term outcome and pattern of failure for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
    Tian, Yun-Ming
    Liu, Ming-Zhu
    Zeng, Lei
    Bai, Li
    Lin, Cheng-guang
    Huang, Shao-Min
    Deng, Xiao-Wu
    Chong-Zhao
    Lu, Tai-Xiang
    Han, Fei
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (05): : 1246 - 1252
  • [2] Intensity modulated radiotherapy (IMRT) in the salvage of recurrent nasopharyngeal carcinoma
    Low, J. S. H.
    Toh, C. K.
    Fong, K. W.
    Chua, E. T.
    Tan, T. W. K.
    Leong, S. S.
    Tan, E. H.
    Wee, J. T. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S435 - S435
  • [3] Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT)
    Kam, M. K.
    Leung, S.
    Yu, K.
    King, A. D.
    Chau, R. M.
    Cheung, K.
    Ma, B.
    Hui, E. P.
    Ahuja, A. T.
    Chan, A. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma
    Fangfang Kong
    Junjun Zhou
    Chengrun Du
    Xiayun He
    Lin Kong
    Chaosu Hu
    Hongmei Ying
    [J]. BMC Cancer, 18
  • [5] Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma
    Kong, Fangfang
    Zhou, Junjun
    Du, Chengrun
    He, Xiayun
    Kong, Lin
    Hu, Chaosu
    Ying, Hongmei
    [J]. BMC CANCER, 2018, 18
  • [6] The Long-Term Recovery of Parotid Glands in Nasopharyngeal Carcinoma Treated by Intensity-Modulated Radiotherapy
    Tasaka, Shun
    Jingu, Keiichi
    Takahashi, Noriyoshi
    Umezawa, Rei
    Yamamoto, Takaya
    Ishikawa, Yojiro
    Takeda, Kazuya
    Suzuki, Yu
    Kadoya, Noriyuki
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Long-term Effect and Prognostic Factors of 582 Nasopharyngeal Carcinoma Patients Treated with Intensity Modulated Radiotherapy
    Feng, M.
    Lang, J.
    Fan, Z.
    Li, J.
    Li, T.
    Wen, H.
    Wang, J.
    Wang, J.
    Wang, J.
    Wang, W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S177 - S177
  • [8] Prognostic Significance of Tumor Volume in Locally Recurrent Nasopharyngeal Carcinoma Treated with Salvage Intensity-Modulated Radiotherapy
    Xiao, WeiWei
    Liu, Shuai
    Tian, YunMing
    Guan, Ying
    Huang, ShaoMin
    Lin, ChengGuang
    Zhao, Chong
    Lu, TaiXiang
    Han, Fei
    [J]. PLOS ONE, 2015, 10 (04):
  • [9] Long-term Results and Prognostic Factors of Primary Nasopharyngeal Carcinoma Patients Treated with Intensity Modulated-Radiotherapy
    Zhao, C.
    Xiao, W.
    Han, F.
    Lu, L.
    Huang, S.
    Wu, S.
    Chen, C.
    Chen, J.
    Lin, C.
    Deng, X.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S630 - S630
  • [10] Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy
    Huang, Tai-Lin
    Chien, Chih-Yen
    Tsai, Wen-Ling
    Liao, Kuan-Cho
    Chou, Shang-Yu
    Lin, Hsin-Ching
    Luo, Sheng Dean
    Lee, Tsair-Fwu
    Lee, Chien-Hung
    Fang, Fu-Min
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E1026 - E1032